Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bionorica Research GmbH
Multiple sclerosis (MS) is in all probability an autoimmune disease causing severe neurological disability due to inflammation and degeneration in the central nervous system (CNS). MS affects over 1 million people worldwide. Central neuropathic pain is associated with approximately 30% of all patients with MS. MS-accompanying pain has a major impact on the patients' quality of life as usual conventional analgesics are little effective. The aim of this clinical study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of multiple sclerosis acc. to McDonald diagnostic criteria
EDSS score between 3 and 8 (incl.)
Patients who are in a stable phase of multiple sclerosis
Patients with MS-related central neuropathic pain for at least 3 months
You may not be if
Severe concomitant diseases
Certain concomitant therapies (in particular: pain influencing concomitant therapies)
Dronabinol intake within the last 12 months prior to study entry or Marihuana use within one month prior to study entry
Clareo Health | Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
